 Leland Shapiro
Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| alpha 1-Antitrypsin | 9 | 2015 | 105 | 1.320 |
Why?
| | alpha 1-Antitrypsin Deficiency | 3 | 2013 | 62 | 0.620 |
Why?
| | Shock, Septic | 1 | 2021 | 219 | 0.590 |
Why?
| | HIV Infections | 6 | 2024 | 3013 | 0.470 |
Why?
| | Meningitis, Cryptococcal | 3 | 2024 | 33 | 0.460 |
Why?
| | Sepsis | 1 | 2021 | 638 | 0.440 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2021 | 1226 | 0.340 |
Why?
| | Cryptococcosis | 2 | 2023 | 31 | 0.330 |
Why?
| | Cryptococcus | 2 | 2024 | 15 | 0.330 |
Why?
| | Interleukin-1beta | 3 | 2014 | 392 | 0.330 |
Why?
| | HIV-1 | 3 | 2015 | 892 | 0.290 |
Why?
| | Nitric Oxide | 2 | 2012 | 899 | 0.280 |
Why?
| | Interleukin-8 | 1 | 2009 | 270 | 0.270 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 255 | 0.270 |
Why?
| | Interferon-gamma | 3 | 2007 | 791 | 0.260 |
Why?
| | Mycobacteriaceae | 1 | 2007 | 32 | 0.250 |
Why?
| | Receptors, CXCR4 | 1 | 2007 | 91 | 0.250 |
Why?
| | Mycobacterium Infections, Nontuberculous | 2 | 2012 | 367 | 0.250 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2007 | 130 | 0.240 |
Why?
| | Interleukin-18 | 1 | 2007 | 236 | 0.230 |
Why?
| | Interleukin-10 | 1 | 2007 | 311 | 0.230 |
Why?
| | Cytomegalovirus | 1 | 2026 | 166 | 0.230 |
Why?
| | Cytomegalovirus Infections | 1 | 2026 | 199 | 0.210 |
Why?
| | Cryptococcus neoformans | 1 | 2024 | 21 | 0.210 |
Why?
| | DNA, Viral | 1 | 2026 | 366 | 0.210 |
Why?
| | Macrophages | 2 | 2012 | 1506 | 0.200 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2024 | 128 | 0.190 |
Why?
| | Anti-HIV Agents | 2 | 2007 | 861 | 0.190 |
Why?
| | Antigens, Fungal | 2 | 2024 | 27 | 0.180 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 169 | 0.160 |
Why?
| | Cytokines | 4 | 2021 | 2097 | 0.160 |
Why?
| | Communicable Diseases, Emerging | 1 | 2020 | 39 | 0.160 |
Why?
| | Medical Errors | 1 | 2020 | 123 | 0.150 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2015 | 1130 | 0.130 |
Why?
| | Islets of Langerhans Transplantation | 2 | 2008 | 75 | 0.120 |
Why?
| | Patient Safety | 1 | 2020 | 340 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2020 | 724 | 0.120 |
Why?
| | Adult | 13 | 2026 | 40012 | 0.120 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1043 | 0.120 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2015 | 13 | 0.120 |
Why?
| | Middle Aged | 11 | 2026 | 35343 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 378 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 373 | 0.110 |
Why?
| | Humans | 22 | 2026 | 143560 | 0.110 |
Why?
| | Research Design | 1 | 2021 | 1123 | 0.110 |
Why?
| | Virus Activation | 1 | 2015 | 86 | 0.110 |
Why?
| | Hypocreales | 1 | 2014 | 8 | 0.110 |
Why?
| | Intraabdominal Infections | 1 | 2014 | 11 | 0.110 |
Why?
| | Virus Replication | 2 | 2021 | 544 | 0.100 |
Why?
| | Mycoses | 1 | 2014 | 87 | 0.100 |
Why?
| | Propensity Score | 2 | 2026 | 350 | 0.100 |
Why?
| | Myeloid Cells | 1 | 2014 | 148 | 0.100 |
Why?
| | RNA, Viral | 2 | 2021 | 704 | 0.090 |
Why?
| | NF-kappa B | 2 | 2015 | 685 | 0.090 |
Why?
| | Male | 14 | 2026 | 71501 | 0.090 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2012 | 172 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2013 | 2417 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1668 | 0.090 |
Why?
| | Female | 14 | 2026 | 77252 | 0.090 |
Why?
| | Dendritic Cells, Follicular | 1 | 2011 | 7 | 0.090 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2012 | 302 | 0.080 |
Why?
| | Monocytes | 1 | 2014 | 545 | 0.080 |
Why?
| | Phosphorylation | 2 | 2012 | 1781 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 352 | 0.080 |
Why?
| | Enzyme Activation | 1 | 2012 | 790 | 0.080 |
Why?
| | I-kappa B Proteins | 1 | 2011 | 76 | 0.080 |
Why?
| | Emphysema | 1 | 2011 | 113 | 0.080 |
Why?
| | Dendritic Cells | 1 | 2014 | 502 | 0.080 |
Why?
| | Epoprostenol | 1 | 2010 | 131 | 0.070 |
Why?
| | Blood Cells | 1 | 2009 | 38 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2575 | 0.070 |
Why?
| | Staphylococcus epidermidis | 1 | 2009 | 77 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 856 | 0.070 |
Why?
| | Risk Factors | 5 | 2024 | 10644 | 0.070 |
Why?
| | Physical Endurance | 1 | 2010 | 278 | 0.070 |
Why?
| | Islets of Langerhans | 1 | 2014 | 825 | 0.070 |
Why?
| | Aged | 7 | 2026 | 25322 | 0.070 |
Why?
| | Placebos | 1 | 2007 | 195 | 0.060 |
Why?
| | Cell Line | 1 | 2012 | 2897 | 0.060 |
Why?
| | Serine Proteinase Inhibitors | 1 | 2007 | 48 | 0.060 |
Why?
| | Immune Tolerance | 1 | 2008 | 381 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2010 | 2017 | 0.060 |
Why?
| | Antihypertensive Agents | 1 | 2010 | 515 | 0.060 |
Why?
| | Transplantation Tolerance | 1 | 2005 | 37 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2014 | 3832 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2011 | 4182 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2011 | 2542 | 0.050 |
Why?
| | Case-Control Studies | 3 | 2018 | 3625 | 0.050 |
Why?
| | Phenotype | 2 | 2012 | 3211 | 0.050 |
Why?
| | Apoptosis | 1 | 2011 | 2519 | 0.050 |
Why?
| | History, 17th Century | 1 | 2020 | 14 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2024 | 537 | 0.040 |
Why?
| | History, 21st Century | 1 | 2020 | 220 | 0.040 |
Why?
| | Mice | 3 | 2012 | 18378 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2010 | 5743 | 0.040 |
Why?
| | History, 20th Century | 1 | 2020 | 327 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2010 | 1957 | 0.030 |
Why?
| | Hyponatremia | 1 | 2018 | 43 | 0.030 |
Why?
| | Mortality | 1 | 2020 | 364 | 0.030 |
Why?
| | Prognosis | 1 | 2026 | 4152 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 280 | 0.030 |
Why?
| | Animals | 4 | 2012 | 38010 | 0.030 |
Why?
| | Cohort Studies | 1 | 2007 | 5891 | 0.030 |
Why?
| | Hospitals, University | 1 | 2016 | 176 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2011 | 1314 | 0.030 |
Why?
| | Inflammation | 1 | 2007 | 2881 | 0.030 |
Why?
| | Clathrin | 1 | 2015 | 26 | 0.030 |
Why?
| | Time Factors | 2 | 2021 | 7032 | 0.030 |
Why?
| | Lysosomes | 1 | 2015 | 130 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2016 | 206 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2018 | 535 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2018 | 16740 | 0.030 |
Why?
| | Cytosol | 1 | 2015 | 225 | 0.030 |
Why?
| | Prospective Studies | 1 | 2007 | 7900 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 505 | 0.030 |
Why?
| | Endocytosis | 1 | 2015 | 169 | 0.030 |
Why?
| | Microbiological Techniques | 1 | 2014 | 34 | 0.030 |
Why?
| | Hearing Loss | 1 | 2018 | 239 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1510 | 0.030 |
Why?
| | Endosomes | 1 | 2015 | 144 | 0.030 |
Why?
| | Young Adult | 3 | 2016 | 13972 | 0.030 |
Why?
| | Antifungal Agents | 1 | 2014 | 147 | 0.020 |
Why?
| | Toll-Like Receptors | 1 | 2014 | 188 | 0.020 |
Why?
| | Peritoneal Dialysis | 1 | 2014 | 97 | 0.020 |
Why?
| | Funnel Chest | 1 | 2012 | 29 | 0.020 |
Why?
| | Logistic Models | 1 | 2018 | 2107 | 0.020 |
Why?
| | Adipokines | 1 | 2012 | 53 | 0.020 |
Why?
| | Gene Frequency | 1 | 2013 | 492 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 2086 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2011 | 53 | 0.020 |
Why?
| | PPAR alpha | 1 | 2011 | 57 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2011 | 58 | 0.020 |
Why?
| | Down-Regulation | 1 | 2014 | 644 | 0.020 |
Why?
| | Polyubiquitin | 1 | 2011 | 6 | 0.020 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2011 | 50 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 138 | 0.020 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2011 | 23 | 0.020 |
Why?
| | Lung Diseases | 1 | 2018 | 787 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 153 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2012 | 354 | 0.020 |
Why?
| | Prevalence | 1 | 2018 | 2830 | 0.020 |
Why?
| | Caspase 3 | 1 | 2011 | 251 | 0.020 |
Why?
| | Ubiquitination | 1 | 2011 | 108 | 0.020 |
Why?
| | Transcription Factor RelA | 1 | 2011 | 87 | 0.020 |
Why?
| | PPAR gamma | 1 | 2011 | 176 | 0.020 |
Why?
| | Smoke | 1 | 2011 | 149 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2011 | 249 | 0.020 |
Why?
| | Scoliosis | 1 | 2012 | 222 | 0.020 |
Why?
| | RNA Interference | 1 | 2011 | 474 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1260 | 0.020 |
Why?
| | Pulmonary Alveoli | 1 | 2011 | 392 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 550 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 423 | 0.020 |
Why?
| | Adolescent | 3 | 2014 | 22482 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2012 | 654 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2014 | 600 | 0.020 |
Why?
| | Up-Regulation | 1 | 2011 | 863 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2008 | 414 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2014 | 11365 | 0.020 |
Why?
| | Colorado | 1 | 2016 | 4658 | 0.010 |
Why?
| | Mice, Inbred C57BL | 2 | 2008 | 6043 | 0.010 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 2005 | 11 | 0.010 |
Why?
| | Chemokine CCL3 | 1 | 2005 | 17 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2008 | 499 | 0.010 |
Why?
| | Chemokine CCL4 | 1 | 2005 | 22 | 0.010 |
Why?
| | Granulocytes | 1 | 2005 | 81 | 0.010 |
Why?
| | Mice, Inbred DBA | 1 | 2005 | 200 | 0.010 |
Why?
| | Walking | 1 | 2010 | 557 | 0.010 |
Why?
| | Body Mass Index | 1 | 2012 | 2430 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2016 | 8072 | 0.010 |
Why?
| | Cell Movement | 1 | 2008 | 973 | 0.010 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2005 | 367 | 0.010 |
Why?
| | Child | 2 | 2014 | 22725 | 0.010 |
Why?
| | Rats | 1 | 2011 | 5610 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 3611 | 0.010 |
Why?
| | Killer Cells, Natural | 1 | 2005 | 475 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2936 | 0.010 |
Why?
| | Interleukin-1 | 1 | 2005 | 970 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4522 | 0.010 |
Why?
| | Heart Failure | 1 | 2014 | 2131 | 0.010 |
Why?
| | United States | 1 | 2018 | 15554 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2008 | 1089 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2621 | 0.010 |
Why?
| | Biomarkers | 1 | 2010 | 4241 | 0.010 |
Why?
| | Exercise | 1 | 2010 | 2152 | 0.010 |
Why?
|
|
Shapiro's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|